MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Retained Earnings 2011-2026 | NDRA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -110 M | -103 M | -91.9 M | -81.9 M | -68.7 M | -57.3 M | -45.2 M | -27.7 M | -17.9 M | -12.5 M | -9.74 M | -7.46 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.46 M | -110 M | -52.9 M |
Quarterly Retained Earnings ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -107 M | -106 M | -104 M | -103 M | - | -96.9 M | -94.7 M | -91.9 M | -90.5 M | -87.4 M | -84.8 M | -81.9 M | -78.6 M | -75.1 M | -71.5 M | -68.7 M | -65.6 M | -62.9 M | -59.7 M | -57.3 M | -55.1 M | -57.3 M | -57.3 M | -45.2 M | -45.2 M | -45.2 M | -45.2 M | -27.7 M | -27.7 M | -27.7 M | -27.7 M | -17.9 M | -17.9 M | -17.9 M | -17.9 M | -12.5 M | -12.5 M | -12.5 M | -12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -12.5 M | -107 M | -57.1 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 15.85 | -2.49 % | $ 171 M |  China |
 |
Agilent Technologies
A
|
348 M | $ 115.06 | -0.29 % | $ 35 B |  USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.13 | -2.59 % | $ 6.15 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 16.05 | -3.83 % | $ 855 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 23.13 | -1.28 % | $ 642 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 2.3 | - | $ 10.2 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 175.65 | 0.06 % | $ 8.71 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Danaher Corporation
DHR
|
46.9 B | $ 189.61 | -1.7 % | $ 135 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 493.53 | -1.59 % | $ 14.2 B | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 120.93 | -2.22 % | $ 19.2 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 14.43 | -3.93 % | $ 436 M | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.35 | -2.03 % | $ 403 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 7.69 | -3.17 % | $ 985 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 78.6 | -9.83 % | $ 9.85 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 2.69 | -1.82 % | $ 87.3 K | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.13 | -0.9 % | $ 4.89 M | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 106.81 | 0.1 % | $ 8.81 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 260.93 | -4.51 % | $ 21.7 B | USA |
 |
Natera
NTRA
|
-1.94 B | $ 193.03 | -4.91 % | $ 19 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 117.14 | -6.02 % | $ 5.48 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 80.59 | -1.03 % | $ 5.44 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 191.51 | -3.19 % | $ 21.3 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.42 | -6.13 % | $ 2.04 B | USA |
 |
Organovo Holdings
ONVO
|
-342 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 16.48 | -3.34 % | $ 369 M | USA |